Toll Free: 1-888-928-9744

CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 29 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Review, H1 2016', provides in depth analysis on CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted pipeline therapeutics. 

The report provides comprehensive information on the CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17)
- The report reviews CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics and enlists all their major and minor projects 
- The report assesses CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) Overview 6 Therapeutics Development 7 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Products under Development by Stage of Development 7 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Products under Development by Therapy Area 8 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Products under Development by Indication 9 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Pipeline Products Glance 10 Early Stage Products 10 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Products under Development by Companies 11 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Products under Development by Universities/Institutes 12 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Companies Involved in Therapeutics Development 19 Sumitomo Dainippon Pharma Co., Ltd. 19 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Drug Profiles 20 CNB-001 - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 KN-93 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 Small Molecule 2 to Inhibit CaM Kinase for Malaria - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 Small Molecule to Inhibit CaM Kinase for Malaria - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Small Molecules to Inhibit CaMKII for Undisclosed Indication - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Dormant Projects 26 CaM Kinase (Ca2+/Calmodulin-Dependent Protein Kinase or EC 2.7.11.17) - Discontinued Products 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 28 Disclaimer 29
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 18 Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 19 Dormant Projects, H1 2016 26 Discontinued Products, H1 2016 27



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify